cap1-6d and Liver-Neoplasms

cap1-6d has been researched along with Liver-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cap1-6d and Liver-Neoplasms

Article	Year
Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma. Chemico-biological interactions, 2022, Sep-25, Volume: 365 Topics: Adenylyl Cyclases; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Oligopeptides; Pyrimidinones; Sorafenib	2022

Article

Year

Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma.

Chemico-biological interactions, 2022, Sep-25, Volume: 365

Topics: Adenylyl Cyclases; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Oligopeptides; Pyrimidinones; Sorafenib

2022